Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-02-10 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届董事会第二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shanghai Medicilon Inc. It discusses the approval of a plan for a targeted issuance of A shares, including specifics on the issuance conditions, pricing, quantity, use of proceeds, and authorization for the board to handle related matters. It also mentions the convening of an extraordinary general meeting (EGM) to approve these matters. The content is focused on corporate governance decisions related to capital raising and share issuance, rather than being a full financial report or earnings release. It is not a simple announcement of voting results but a comprehensive board meeting resolution document. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it details the company's financing activities and capital structure changes through a targeted share issuance plan.
2022-02-10 Chinese
美迪西：2022年度向特定对象发行A股股票方案的论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Shanghai Medicilon Inc. regarding a 2022 plan to issue A shares to specific investors. It includes extensive background analysis, market data, regulatory references, issuance pricing, investor selection criteria, and the rationale for the capital raise. The text discusses the company's business, the necessity of the capital raise, and compliance with relevant securities laws and regulations. The document is lengthy (15,000 characters) and contains substantive content about the capital raising plan, including financial impact analysis and issuance details. It is not a brief announcement or a simple notification but a comprehensive report supporting a capital/financing activity. Therefore, the document fits the category of Capital/Financing Update (CAP).
2022-02-10 Chinese
美迪西：前次募集资金使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the usage of previously raised funds, detailing the amount raised, usage, management, and investment projects related to the company's prior fundraising activities. It references regulatory requirements from the China Securities Regulatory Commission and includes detailed financial figures on fundraising and usage up to September 30, 2021. The document is not a full annual or interim report but a specific report on the use of raised capital, which aligns with the definition of a Capital/Financing Update (CAP). It is not an announcement of a report publication but contains substantive financial data and analysis on fundraising usage. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-02-10 Chinese
美迪西：独立董事关于第三届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 85% confidence The document is an independent opinion report from independent directors regarding a specific board meeting's agenda about a targeted issuance of A shares by the company. It discusses compliance with laws, the issuance plan, analysis reports, use of funds, dilution impact, and shareholder return plans. The content is focused on governance and approval of a capital raising plan rather than the capital raising announcement itself or a full financial report. The document length is short (2252 characters) and it is a formal opinion related to board matters and issuance plans, not a full capital/financing update or annual/interim report. This fits best under Board/Management Information (MANG) as it relates to board meeting opinions and approvals on financing matters, rather than the financing update itself (CAP) or regulatory filings (RNS).
2022-02-10 Chinese
美迪西：关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2022 first extraordinary general meeting (临时股东大会) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods, agenda items, shareholder registration, and proxy forms. The content focuses on the announcement and procedural details of the shareholders' meeting rather than the meeting materials or results. The document length is 4233 characters, which is relatively short and consistent with a meeting notice rather than a full report or results announcement. There is no indication that this is a report publication announcement or voting results declaration. Therefore, the document fits best into the category of a Proxy Solicitation & Information Statement (PSI), as it provides information and requests votes for the meeting.
2022-02-10 Chinese
美迪西：关于向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanghai Medicilon Inc. regarding a specific issuance of A shares to particular investors. It discusses the impact of this issuance on earnings per share, dilution of immediate returns, and the company's measures and commitments to compensate for this dilution. The document includes detailed financial assumptions, risk warnings, and commitments from controlling shareholders and management. It is focused on capital raising activities and the related financial and governance implications. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content aligns with updates on company fundraising and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7110 characters) and detailed financial impact analysis support this classification with high confidence.
2022-02-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.